Lonnel Coats, Lexicon CEO
Deserted by Sanofi, Lexicon discloses last-minute hiccup in its solo fight to get sotagliflozin approved
When the FDA first snubbed Sanofi and Lexicon’s NDA for sotagliflozin back in 2019, the rejection quashed their hopes of scoring a last-place finish in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.